116 patients were randomised to ingest Lactobacillus reuteri (1 x 10^8 CFU/day) for 60 days (n=58) or no probiotic supplement (n=58). Daily intake of Lactobacillus reuteri significantly increased the proportion of patients that were free from diarrhoea compared to the control group: 62% and 50%, respectively.
Patients who ingested Lactobacillus reuteri and got diarrhoea were less likely to have grade 2 diarrhoea events than patients in the control group: 28% (6/22) vs. 90% (26/29). (Grade 2 = increase of 4-6 stools over baseline but not interfering with activities of daily living.)
Abdominal pain control was completely obtained in 86% in the L. reuteri group vs. 79% in the control group. Lactobacillus reuteri was safe to ingest for this type of patients.
Conclusions: The supplementation with Lactobacillus reuteri was safe and minimized the diarrhoea incidence in colon cancer patients receiving fluorofolates with or without oxaliplatin. Abdominal pain was also reduced.